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Background: Respiratory Syncytial Virus (RSV) is an important human respiratory pathogen, particularly of infants and
older adults, and despite several decades of research and development, no licensed vaccine is available. Studies have
confirmed that enhancement of RSV disease does not occur after inoculation with RSV live-attenuated vaccine
candidates, making such vaccines preferable. In this paper, reverse genetics was used to construct two recombinant
viruses, a recombinant Long strain (rLong) and rLong-ΔG-EGFP; rLong-ΔG-EGFP is a recombinant mutant in which G
was replaced with the EGFP gene, based on the Long strain of RSV.
Results: Both rLong and rLong-ΔG-EGFP were constructed successfully and recovered in Hep-2 cells, and
autofluorescence was observed in rLong-ΔG-EGFP-infected cells during consecutive passages. Titers of rLong and
rLong-ΔG-EGFP were ~100-fold lower than the parental strain. Although virulence was attenuated, high titers of
neutralizing antibodies were induced in BALB/c mice after being inoculated with recombinant viruses in a
three-dose schedule. Unexpectedly, the neutralizing antibody titer in rLong-ΔG-EGFP-immunized recipients did not
decline significantly compared with the rLong strain. Protective efficacy of recombinant viruses in lung tissue was
up to 100%, and the serum neutralizing antibody levels could stabilize at 21 days with no significant fall
post-challenge. Enzyme-linked immunospot (ELISPOT) assays showed that both recombinant viruses were capable
of inducing CD8+ T cell immune responses, which are crucial for virus clearance, and that rLong stimulated a higher
level of IFN-γ production by comparison. In terms of inducing a balanced immune response, rLong-ΔG-EGFP elicited
slightly higher levels of IgG2a antibodies and lower levels of IgG1/IgG2a than the rLong virus.
Conclusions: This study suggested that immunization with rLong and rLong-ΔG-EGFP were immunogenic and
protected against RSV infection in the lower respiratory tract of BALB/c mice better than in the nose. Because of a
relative low IgG1/IgG2a ratio, rLong-ΔG-EGFP was more inclined to make CD4+ T cells, shifting toward a Th1-type
response, indicating that the generation of a more balanced Th1/Th2 response was desirable. This explorative study on
the recombinant Long viruses also contributed to obtaining more RSV attenuated candidates by a reverse genetics
approach.
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Respiratory Syncytial Virus (RSV) is an important pathogen
of lower respiratory tract infections in newborn and young
children, and also a cause of severe lower respiratory tract
inflammation in elderly and immunosuppressed patients.
More than half of children are infected within their first
year of life [1,2]. Because of its high infection rate, the
World Health Organization (WHO) has attached great im-
portance to developing a vaccine. In the 1960s, the develop-
ment of a formalin-inactivated RSV (FI-RSV) vaccine did
not produce a protective effect in vaccinated recipients; in-
deed, on the contrary, it resulted in 80% of the patients be-
ing hospitalized, with two deaths. The enhanced severity of
the disease was thought to have resulted from the poor pro-
duction of neutralizing antibodies, excessive induction of a
type 2 helper T cell-like (Th2) immune response, with pul-
monary eosinophilia, and failing to induce a MHC I-
restricted CD8+ T cell immune response [3]. Despite several
decades of research and development since then, no li-
censed vaccine is currently available.
RSV is a non-segmented negative-sense single-stranded
RNA virus belonging to the Paramyxoviridae family. The
genome of RSV is 15.2 kb long, encoding 11 proteins
[4,5]. After the failure of the FI-RSV vaccine, further ef-
forts have been made toward the development of safe and
effective RSV vaccines without inducing vaccine-enhanced
disease [6]. Several strategies for RSV vaccine research are
being developed [7,8], including a protein subunit-based
vaccine, live-attenuated RSV vaccine, and viral vector-
based candidates. The F and G glycoproteins are two
major protective antigens in inducing neutralizing anti-
bodies against virus infection. Currently, protein subunit-
based vaccines have been designed focusing mainly on the
F, G, and M2 proteins, such as BBG2Na, a subunit vaccine
derived in part from the G protein of RSV-A, the PFP
series vaccine, targeting purified F protein, as well as a re-
combinant chimeric protein of G and M2 protein epi-
topes, such as G1-F/M2. Many protein subunit-based
vaccines have been evaluated in preclinical and clinical
tests. The BBG2Na vaccine was well tolerated in phase II
clinical studies, but a further trial had to be stopped due
to unexpected adverse events [9,10]. Vaccination with PFP
was immunogenic in a population of pregnant women,
children, and old people [11,12]. However, in fact, the inci-
dence of RSV-caused diseases did not significantly de-
crease. Another recombinant subunit vaccine G1-F/M2,
designed by Mei’s group, induced CD8+ T cell responses, a
balanced IgG1/IgG2a response, and a high level of neu-
tralizing antibody [13,14], suggesting that the G1-F/M2 fu-
sion protein has potential as a subunit RSV vaccine; its
development is still in the early stages of laboratory work.
Studies have already confirmed that enhancement of
RSV disease does not occur after natural RSV infection or
inoculation with RSV live-attenuated vaccine candidates[15]. RSV live-attenuated candidates simulate the process
of natural infection well, and immune pathological effects
have not been observed post-challenge; these are import-
ant facts suggesting that a live-attenuated RSV vaccine is
preferable. the rapid development of molecular biology
has facilitated the manipulation of the viral genome. In-
deed, many mutant RSVs have been produced from cDNA
clones, so attenuating mutations could be readily intro-
duced into the RSV genome via reverse genetics tech-
niques [16].
A recombinant RSV bearing a deletion of the NS2 or SH
gene is attenuated in chimpanzees; rA2ΔNS2 replicated to
moderate levels in the upper respiratory tract and was
highly attenuated in the lower respiratory tract but induced
sufficient resistance to challenge with wild-type RSV [17].
An RSV lacking the open reading frame (ORF) of the M2
gene (M2-2) has altered growth characteristics and is atten-
uated in rodents [18]. Despite its attenuated replication in
rodents, rA2ΔM2-2 was also able to provide protection
against challenge with wild-type RSV A2, and the genotype
or phenotype of the M2-2 deletion mutant was stably main-
tained after extensive passages in vitro. Another RSV mu-
tant strain, rRSVΔG, lacking the G protein (ΔG), was
constructed based on a clinical isolate strain (strain 98-
25147-X). rRSVΔG replicated well in vitro, and the data
indicated that a single-dose immunization with the highly
attenuated ΔG conferred long-term protection in the cot-
ton rat against RSV challenge subsequently without indu-
cing vaccine-enhanced pathology [19]. Recombinant RSV
mutants lacking the SH, NS2, G, or M2-2 gene are attenu-
ated, and these deletion strategies can be used for attenu-
ated mutations in new, live recombinant RSV candidate
development [20].
In this paper, we describe a reverse genetics system for
the RSV Long strain. The full-length antigenomic cDNAs
of a recombinant Long strain (rLong) and rLong-ΔG-EGFP
were flanked by a hammerhead ribozyme (HamRz) and
hepatitis delta virus ribozyme (HdvRz), and were placed
under the control of a T7 promoter of a modified pBR322
vector. A set of helper plasmids encoding nucleoprotein
(N), phosphoprotein (P), Large protein (L), and Matrix pro-
tein (M2-1) were constructed and co-transfected with plas-
mids containing the full-length cDNA clone of the
recombinant viruses into Hep-2 cells that were previously
infected with a recombinant vaccinia virus vTF7-3 express-
ing T7 RNA polymerase. With the assistance of the T7
RNA polymerase, both recombinant viruses were recovered
successfully and rLong-ΔG-EGFP generated stable fluores-
cence spontaneously during multiple viral passages in cul-
tured cells subsequently.
Here, we constructed an rLong and a mutant form of
RSV (rLong-ΔG-EGFP). Because previous studies have
revealed that the G gene is not necessary for effective
replication of several RSV strains in vitro [19], in this
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studied in Hep-2 cells and the immunogenicity for the
recombinant and the ΔG Long viruses were evaluated in
a BALB/c mouse model.Results
Construction and identification of rLong and rLong-ΔG-
EGFP full-length cDNA clones
A recombinant full-length cDNA clone of the RSV Long
strain was constructed by stepwise assembly of six
cDNA fragments, and the G gene within fragment C
was replaced with an EGFP gene for constructing
rLong-ΔG-EGFP. Four helper plasmids carrying the N,
P, L, and M2-1 genes of the Long strain were also con-
structed in the pCI vector. The respective resulting gen-
omic sizes for rLong and rLong-ΔG-EGFP were 15,222
base pairs (bp) and 15,050 bp, theoretically, and the
gene sizes for the helper genes N, P, L, and M2-1 were
1,176, 726, 6,498, and 585 bp, respectively. All plasmids
were subjected to restriction endonuclease digestion,
and the constructs were further confirmed by DNA se-
quencing. The restriction endonuclease digestion results
were assessed using 1% agarose gel electrophoresis. The
fragment sizes of rLong, rLong-ΔG-EGFP, N, P, L, and
M2-1 were consistent with the corresponding gene sizes
(Figure 1). Recombinant plasmids were finally con-
firmed by DNA sequencing. The nucleotide sequences
of the full-length genomes of rLong and rLongΔG-
EGFP and the four helper structural protein genes were
the same as the Long strain sequence in GenBank
(AY911262.1). No mutation, including deletions or re-
location, occurred during cloning.Figure 1 Identification of pRSV, pRSVΔG-EGFP and four helper plasm
DNA Ladder DL15000; 1, pRSV was digested with sal I and kpn I (length 15
I (length 15050 bp, 4108 bp); (B) Restriction patterns of pCN-N and pCI-P h
(length 1176 bp, 4006 bp); 4, plasmid pCI-P was digested with NheI and Kp
pCI-M2-1 helper plasmids. 5, plasmid pCI-L was digested with XhoI and Sal
XhoI and XbaI (length 585 bp, 4006 bp).Recovery and characterization of recombinant viruses
from cDNA clones
rLong and rLong-ΔG-EGFP cDNA expression were driven
by T7 RNA polymerase, supplied by a vaccinia-T7 recom-
binant virus, based on the vTF7-3 strain. However, recom-
binant vaccinia virus vTF7-3 produced an amount of
infectious progeny that was sufficient to cause extensive
cytopathogenicity upon passage. Thus, cytosine arabino-
side, an inhibitor of vaccinia virus replication was added
24 h after the transfection and maintained during the first
nine passages. Further purification of the recovered re-
combinant viruses was carried out by multiple plaque
purification procedures. Plaque morphology for the rLong
virus was smaller than the parental wild-type Long virus,
but the size of the plaques was relatively uniform. Further
comparisons showed no apparent morphological differ-
ence between the rLong and its ΔG mutant strain
(Figure 2).
The successful recovery of rRSV was confirmed by an
indirect immunofluorescence assay (IFA) staining with an
anti-RSV G polyclonal antibody and sheep anti-rabbit im-
munoglobulin G labeled with horseradish peroxidase
(HRP) successively. The expression of enhanced green
fluorescent protein (EGFP) of rLong-ΔG-EGFP in the
cytoplasm of Hep-2 cells at the third day post-transfection
was observed directly using fluorescence microscopy. The
rLong-ΔG-EGFP-infected cells were fluorescent, whereas
cells mock-infected with rLong or the parental RSV Long
strain were not (Figure 2). This demonstrated that the re-
combinant virus carrying the EGFP gene was rescued suc-
cessfully and that the reporter gene was expressed in the
cytoplasm of transfected cells. The recovery of recombin-
ant viruses was also confirmed by polymerase chainids. (A) Restriction patterns of cDNA clones of pRSV, pRSVΔG-EGFP. M,
222 bp, 4108 bp); 2, pRSVΔG-EGFP was also digested with sal I and kpn
elper plasmids. 3, plasmid pCI-N was digested with EcoRI and KpnI
nI (length 726 bp, 4006 bp); (C) Restriction patterns of pCN-L and
I (length 6498 bp, 4006 bp); 6, plasmid pCI-M2-1 was digested with
Figure 2 Identification of recovered recombinant viruses by
fluorescent assay and plaque assay. (A) the successfully recovery
of rLong was confirmed through indirect immune fluorescent assay
by immune-staining with an anti-RSV G1 polyclonal antibody
targeting G protein epitopes as the first antibody. (B) the recovery
of rLong-ΔG-EGFP was evaluated by observating under fluorescent
microscope. (C) the negative control was Hep-2 cells without
infected by viruses. (D-F) Plaque morphology for wild-type RSV
long virus, rLong and rLong-ΔG-EGFP respectively.
Hu et al. Virology Journal 2014, 11:142 Page 4 of 16
http://www.virologyj.com/content/11/1/142reaction (PCR) with two sets of primers (pF-G, pR-G and
pF-EGFP, pR-EGFP). PCR amplification indicated that the
G gene was not present in rLong-ΔG-EGFP (no 750-bp
gene product was amplified; Figure 3A). Simultaneously,
the EGFP fragment, of ~750 bp could be amplified from
rLong-ΔG-EGFP, but not the RSV Long strain or rLong
(Figure 3B); these results were consistent with our initial
design.Figure 3 Identification of recovered recombinant viruses by
PCR. (A) Amplification patterns of G gene for recovered viruses. lane
1, 2, RT-PCR product of RSV long strain and the recovered rLong
(length 897 bp); lane 3, PCR product without band for rLong-ΔG-
EGFP. (B) identification of EGFP gene for recovered viruses. lane 1, 2,
PCR product without any amplification band, lane 3, The RT-PCR
products of EGFP gene (length 750 bp) for rLong-ΔG-EGFP was
electrophoresed through a 1% agarose gel.Stability of rLong-ΔG-EGFP passaged in Hep-2 cells
To examine the genetic stability of rLong-ΔG-EGFP in
Hep-2 cells, serial passages from 1 to 9 were carried out.
After nine consecutive passages of rLong-ΔG-EGFP, every
generation of the ΔG mutant in infected Hep-2 cells was
confirmed by direct observation under a fluorescence
microscope. Results suggested that the various generations
of recombinant virus (P1-P9) could produce stable auto-
fluorescence (Figure 4). rLong-ΔG-EGFP was apparently
stable for the indicated passages in terms of the expression
of EGFP.
Replication of recombinant viruses in Hep-2 cells and
BALB/c mice
Hep-2 cell monolayers were infected with the parental
Long strain, rLong, or rLong-ΔG-EGFP with a multiplicity
of infection (MOI) of 0.1 and incubated at 37°C. Viruses
were harvested at five indicated time points, and virus ti-
ters [plaque formation units (PFU) ml−1] were determined
by plaque assays. Each viral titer value is the mean titer of
two wells of infected cells. The viral growth curve is
shown below (Figure 5). rLong and rLong-ΔG-EGFP
showed similar growth kinetics. The wild-type parental
Long strain reached a titer of up to 107 PFU ml−1 in Hep-
2 cells (maximum titers of 107.4 PFU ml−1), while the re-
covered rLong and rLong-ΔG-EGFP harvested from the
supernatants and transfected Hep-2 cells after three
freeze–thaw cycles reached titers of 2.9 × 105.4 and 7.6 ×
104.9 PFU ml−1, respectively. The titer was ~100-fold
lower than the parental Long strain of RSV. Unexpectedly,
the titer of rLong-ΔG-EGFP apparently did not decrease
compared to rLong.
Each animal was infected intranasally (i.n.) with 105
PFU (recombinant) RSV and killed on days 3, 5, and 7
post-inoculation. Lung tissues and nasal tissue lavages
were collected for virus titration in Hep-2 cells. The re-
sult showed that high titers of virus were found on daysFigure 4 Stability research of the recovered virus rLong-ΔG-EGFP.
A-I represented nine consecutive passages of rLong-ΔG-EGFP on Hep-2























Figure 5 Growth of (recombinant) viruses in Hep-2 cell lines. Growth characteristic of RSV long strain and two recovered viruses rLong and
rLong-ΔG-EGFP in Hep-2 monolayers. viruses were harvested at the indicated time points and virus PFU titers were determined, Each value is the
mean titer of two wells at indicated time points.
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virus were detected on day 7 in RSV-Long-immunized
mice. In rLong and rLong-ΔG-EGFP inoculated mice,
the replication of the virus declined apparently as
compared with the parental Long strain. The maximum
titers of virus in the lower respiratory tract of rLong-
immunized mice were 103.2 and 102.86 on days 3 and 5,
respectively, slightly higher than in the nose. We also
found that replication of rLong-ΔG-EGFP was lower
than that of rLong in the lungs and nose. In fact, replica-
tion of the rLong-ΔG-EGFP in lungs and nose was
below the limit of detection on days 5 and 7 (Table 1).
According to a study on the replication of recoveredTable 1 Replication of recombinant RSV in the upper and




Mean titer ± SDc Mean titer ± SDc
(log10 PFU g
−1) (log10 PFU ml
−1)
3 RSV-Long 4.52 ± 0.29 3.62 ± 0.52
rLong 3.20 ± 0.18 2.50 ± 0.12
rLong-ΔG-EGFP 2.76 ± 0.36 <1.98
5 RSV-Long 4.42 ± 0.60 3.48 ± 0.25
rLong 2.86 ± 0.32 2.05 ± 0.08
rLong-ΔG-EGFP <2.68 <1.98
7 RSV-Long 2.95 ± 0.224 2.65 ± 0.15
rLong <2.68 <1.98
rLong-ΔG-EGFP <2.68 <1.98
aBALB/c mice were inoculated with 105 PFU of (recombinant) virus. bLungs
and nasal washes were collected, and virus titers were determined on the
indicated day: 3, 5, or 7. cThe lower limits of detection for virus in the lungs
and nose were 2.68 log10 PFU g
−1 and 1.98 log10 PFU ml
−1, respectively. Each
group consisted of six animals.virus in vivo, we also found that the virulence of rLong-
ΔG-EGFP was less than 1 log attenuated on day 3, sug-
gesting that for the RSV Long virus, the replacement of
G with the EGFP gene made a less attenuated phenotype
in BALB/c mice.
Determining neutralizing antibody titers against RSV
The neutralizing antibodies in mice serum, lung tissue,
and nasal tissue lavage (NTL) after immunization with
the three viral antigens were measured using plaque re-
duction assays. Plaques were counted and plaque reduc-
tion was calculated by regression analysis to provide a
60% plaque reduction titer (log3). Neutralizing antibody
titers in serum and lung tissue were approximately only
1:1.6 and 1:1.2, respectively, in FI-RSV-immunized mice.
The values in serum and lung tissue for both rLong and
rLong-ΔG-EGFP were significantly higher than that of
FI-RSV (~1:89.4 and 1:63.6, and ~1:69.4 and 1:47.3, re-
spectively; Figure 6). Further comparisons showed that
the antibody induced by rLong-ΔG-EGFP continued to
have high neutralizing activity; the neutralizing antibody
titer did not decrease significantly. However, the viral
titer and immunogenicity of rLong-ΔG-EGFP was af-
fected only slightly. Meanwhile, FI-RSV induced ex-
tremely low levels of neutralizing antibodies, which may
be one of the reasons that FI-RSV did not show protect-
ive effects in Balb/c mice.
Serum neutralizing antibody titers in FI-RSV, rLong,
or rLong-ΔG-EGFP pre-immunized mice serum was de-
termined on days 3, 5, 7, 10, and 21 post-challenge. Gen-
erally, neutralizing antibody levels increased slightly after
virus infection. However, a declining time point occurred
on day 5 (Figure 7). A possible reason may be that RSV
replicated rapidly in BALB/c mice up to day 5 post-
Figure 6 The neutralizing antibody induced by FI-RSV, rLong and rLong-ΔG-EGFP. 6–8 week-old balb/c mice were divided into three
groups and were immunized with FI-RSV, rLong and rLong-ΔG-EGFP respectively on days 0, 7, 14. 10 days after all immunization procedure was
completed, Mean neutralizing antibodies in mice serum after immunization with three antigens was shown above. Groups consisted of 4 animals.
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by massive virus multiplication. Further analysis revealed
that neutralizing antibody levels stabilized to 21 days,
without showing any significantly fall compared with
that on day 10 post-challenge. In contrast, the serum
neutralizing antibody in FI-RSV-vaccinated BALB/c mice
was maintained at an extremely low level.
Protectivity of recombinant viruses
Mice in each experimental group were killed on days 3,
5, 7, 10, and 21, and the lung tissue was removed and
homogenized in an appropriate volume of phosphate-
buffered saline (PBS). Viral titers of lung tissue in mice
immunized with both recombinant viral antigens were
lower than 2.68 log PFU ml−1, with no detectable virusFigure 7 The neutralizing antibody changes after virus challenge. Afte
challenged with 106 pfu RSV long strain preparations and the neutralizing
challenge. Trends of neutralizing antibody level after RSV challenge in mice
Groups at each time point consisted of 4 animals.in the lower respiratory tract at the indicated time
points. The protective efficacy of the recombinant vi-
ruses in lung tissue was up to 100%. However, a lower
level of virus could be detected in the NTL in rLong-
and rLong-ΔG-EGFP-immunized BALB/c mice. The de-
tectable viral titers in NTL were within the ranges of
2.58–2.96 log PFU ml−1 and 2.25–3.17 log PFU ml−1, re-
spectively (Table 2). This suggested that protective effi-
cacy of the recombinant virus in the lower respiratory
tract may be much better. However, in the mock group,
high titers of virus, >4.0 log PFU ml−1 on day 7 post-
challenge, could still be detected in the lungs or nose.
With FI-RSV immunization, the situation was appar-
ently worse and no protection occurred in the lungs or
nose.r all the immunizations being completed, mice were intranasally
antibody in serum was determined on day 3, 5, 7, 10, 21 post
pre-immunized with FI-RSV, rLong or rLong-ΔG-EGFP was shown.




Mean RSV titer ± SDd log
PFU ml−1
Mice protectedc (%) Mean RSV titer ± SDd log
PFU ml−1
Mice protectedc (%)
FI-RSV RSV-Long 3 4.56 ± 0.28 0 4.98 ± 0.38 0
5 5.11 ± 0.45 0 5.28 ± 0.55 0
7 4.78 ± 0.36 0 5.08 ± 0.25 0
10 4.96 ± 0.20 0 4.85 ± 0.48 0
21 3.38 ± 0.18 0 3.55 ± 0.33 0
rLong RSV-Long 3 <2.68 100 2.58 ± 0.28 75
5 <2.68 100 2.96 ± 0.20 75
7 <2.68 100 <1.98 100
10 <2.68 100 <1.98 100
21 <2.68 100 <1.98 100
rLong-ΔG-EGFP RSV-Long 3 <2.68 100 2.69 ± 0.24 75
5 <2.68 100 3.17 ± 0.16 50
7 <2.68 100 2.25 ± 0.21 75
10 <2.68 100 <1.98 100
21 <2.68 100 <1.98 100
Mock RSV-Long 7 4.18 ± 0.25 0 4.03 ± 0.20 0
Mock Mock 7 <2.68 100 <1.98 100
aBALB/c mice were infected with 106 PFU (100 μl) of the indicated virus (RSV-Long) at day 0. bLungs and nasal washes were harvested, and virus titers were
determined at the indicated times. cResidual titers of RSV in the lung and nasal washes at the indicated time points post-challenge; protective efficacy of animals
for the indicated groups of mice (FI-RSV, rLong, rLong-ΔG-EGFP). dThe lower limits of detection for virus in the lungs and nose were 2.68 log10 PFU g
−1 and 1.98
log10 PFU ml
−1, respectively. Groups at indicated time point consisted of four animals.
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Titers of serum IgG antibody subtype, represented as
IgG1 and IgG2a, were determined on days 0, 3, 5, 7, and
10 post-challenge, and the corresponding ratio of IgG1/
IgG2a was calculated (Figure 8). Experimental results re-
vealed that the serum IgG1/IgG2a ratios in mice immu-
nized with rLong and rLong-ΔG-EGFP were significantlyFigure 8 Subtype analysis of mice serum IgG antibody. Titers of serum
determined on day 0, 3, 5, 7, 10 post RSV challenge and the corresponding
Groups at each time point consisted of 4 animals. the black bars, bars with
FI-RSV, rLong, rLong-ΔG-EGFP and Mock respectively.lower than with FI-RSV. In this study, recombinant viruses
with attenuated virulence tended to produce higher levels
of IgG2a antibody response, suggesting a Th1-biased im-
mune response. However, in FI-RSV-immunized BALB/c
mice, high levels of IgG1 antibodies were produced, indicat-
ing that a more balanced Th1/Th2 response was induced
by the recombinant viruses. Further comparison found thatIgG antibody subtype represented as IgG1 and IgG2a were
ratio of IgG1/IgG2a was also calculated, the result was shown above.
slashes, gray bars and bars with vertical lines are representative of
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than rLong, demonstrating that rLong-ΔG-EGFP per-
formed better from the perspective of a balanced T cell im-
mune response because the G glycoprotein was absent
from the genome of the RSV.Cellular immune response induced by RSV antigens
At 7 days after the last immunization, mice were killed
and spleens were removed to allow isolation of splenic
lymphocytes. IFN-γ and IL-2 secretion in lymphocytes
stimulated with RSV antigen in vitro were determined
by an enzyme-linked immunospot (ELISPOT) assay.
The results are expressed as spot-forming cells (SFCs)
per million lymphocytes (Figure 9). Mean SFCs with the
secretion of IFN-γ with rLong stimulated by RSV anti-
gen reached 108 SFCs/106 lymphocytes, which was
greater than with rLong-ΔG-EGFP (78 SFCs/106 lym-
phocytes), while FI-RSV induced only 9 SFCs/106 lym-
phocytes. Mean SFCs secreting IL-2 induced by the RSV
antigen reached 42 SFCs/106 and 35 SFCs/106 lympho-
cytes in rLong and rLong-ΔG-EGFP pre-immunized
mice spleens, respectively. Statistical analyses showed
significant differences between rLong and rLong-ΔG-
EGFP for secretion of IFN-γ (t = 6.253, p = 0.024), but
no significant difference was observed between rLong
and rLong-ΔG-EGFP for the secretion of IL-2 (t = 1.235,
p = 0.075). This study demonstrated that both recom-
binant viruses were capable of inducing CD8+ T cell re-
sponses, and rLong induced a higher level of IFN-γ
production.Figure 9 The indicated virus-specific T-cell immune responses in imm
cells (SFCs) of indicated virus-specific IFN-γ-producing cells per million lymp
rLong-ΔG-EGFP was shown with black bars, and the IL-2-producing cells pe
was shown with gray bars. The IFN-γ and IL-2 ELISPOT assays in FI-RSV, rLo
the indicated long virus antigen (40 μg/ml) for 16-20 h while the concentr
control was stimulated by PBS. Experiments were performed with three mi
were statistically significant for IFN-gamma, but not significant for IL-2 betwDiscussion
In the RSV genome, the G protein is an envelope glyco-
protein that is the most important and vulnerable to
antigenic variation. Thus, RSV was divided into two sub-
types, A and B, according to the antigenic and genetic
differences, mainly within the G protein [21]. The pre-
dominant subtype of RSV belongs to type-A, which pre-
vails in most areas of China; the A-subtype of the virus
is also more pathogenic [22]. The A2 and Long strains
are two “standard” RSV-A subtypes. In this study, the
Long strain of RSV was chosen for reverse genetics
research.
To date, several examples have been reported regard-
ing the successful construction of full-length infectious
cDNA clones based on RSV-A2, X, and Long strains
[23]. RSV-A2 was originally isolated in the 1960s, while
RSV-X is a clinical isolate strain, 98-25147-X, isolated in
1998; the RSV Long strain is a strain of VR-26D from
the American Type Culture Collection (ATCC). Previous
research focused mainly on the RSV-A2 strain, including
its different mutant forms, such as the deletions of G,
SH, NS1, and NS2 genes, which have been studied ex-
tensively in vivo and in vitro [20]. Reverse genetics sys-
tems for RSV-X, a clinical RSV isolate, and RSV-X-ΔG
were also reported [19]. The principles and methods for
the construction and recovery of these strains are almost
the same as those for the laboratory BRSV isolate strain
A51908, described by Yunus [24], including plasmids en-
coding the full-length viral antigenome and plasmids
containing the viral structural protein genes N, P, L, and
M2-1. Then, the resulting five plasmids were transfectedunized mice by ELISPOT assay. The mean number of spot-forming
hocytes from Balb/c mice pre-immunized with FI-RSV, rLong or
r million lymphocytes from corresponding pre-immunized Balb/c mice
ng or rLong-ΔG-EGFP groups were performed with the stimulation of
ation of positive stimulus PMA or ConA is 10 ug/ml, the negative
ce per group. The data were analyzed by t test, and the differences
een rLong and rLong-ΔG-EGFP.
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purpose of obtaining infectious recovered viruses. Lo
et al. reported that rLong was rescued in BHK-SR19 cell
lines using the Sindbis virus expressing T7 RNA poly-
merase [25]. However, no follow-up studies were re-
ported on this recombinant virus. Our work represents
another Long virus reverse genetics system, which is
similar to that of Lo et al., except for the source of the
T7 RNP (a recombinant vaccinia vTF7-3) and the cell
lines used for virus recovery. Beyond establishment of
the reverse genetics system, further studies on viral pas-
sage and an immunogenicity study of the recovered
Long virus are reported in this paper.
Replication of the recovered virus showed that titers of
rLong were ~100-fold lower in vitro than the parental
strain, and that the replication of rLong-ΔG virus declined
slightly compared with rLong. These results were consist-
ent with the previous work on RSV-A2 and RSV-X reverse
genetics systems, with recovery in Vero, 293 T, and A549
cells [19]. We hypothesized that these reduced recombin-
ant viral titers in vitro may be as a result of the efficiency
limits with recombinant plasmids transfection and virus
rescue system. Replication of rRSV-X-ΔG in the cotton rat
is highly attenuated. Indeed, the ΔG virus had no detect-
able viral load in the lungs of cotton rats on day 3 [19].
This was consistent with the work from the Collins lab at
the National Institutes of Health (NIH) where the ΔG was
generated in the background of strain A2 [26], but the ΔG
viruses for both the A2 and X strains were considered to
be over-attenuated as vaccine candidates. Unexpectedly,
we found that the virulence of our rLong-ΔG strain was
less than 1 log attenuated in the lung of Balb/c mice on
day 3, indicating that the rLong-ΔG virus was not over-
attenuated. Thus, this newly constructed ΔG virus may be
less attenuated than previously described ΔG mutants.
That is, the Long strain may be less dependent on G for
in vivo replication than the X or Long strain and may
therefore be more suitable for attenuated vaccine strain
screening. This is an important finding of our study on
the recombinant ΔG Long virus. G protein is not required
for infection in vitro but it may be an important stimulus
for efficient RSV growth in vivo [19,27], and the Long-ΔG
virus may be useful for finding the appropriate level of at-
tenuation in recipients without sacrificing immunogen-
icity and ensuring a less attenuated phenotype. Indeed, an
rRSV strain with the G protein deleted was rescued suc-
cessfully [28]. However, the complete absence of the G
protein severely restricted replication in vivo and thus lim-
ited the potential of the rRSV as a vaccine, as seen with
the A2 and X strains [19,29]. Although the G protein is
not an essential ingredient for viral replication in vitro, the
viral titer and immunogenicity of the ΔG mutant could be
affected. However, in this study, although viral virulence
of recombinant ΔG long viruses was diminished, hightiters of neutralizing antibodies for our rLong-ΔG virus in
mice were induced and the protective antibody titers per-
sisted for up to 21 days post-challenge with no significant
decline. Furthermore, the protective efficacy of the rLong
virus in lung tissue was up to 100%. In contrast, residual
virus could be still detected in the NTL, which also sug-
gested that the protective efficacy of our recombinant
virus in the lower respiratory tract was better than in the
nose. Alternatively, we also considered that the F protein
is one of the major stimuli for virus neutralizing anti-
bodies, which may be why titers of neutralizing antibodies
did not decrease significantly with rLong-ΔG-EGFP.
For RSV vaccine candidates, the CD8+ T cell response
has special significance because the CD8+ T cell re-
sponse is not only directly involved in clearing virus and
virus-infected cells but also potentially regulating CD4+
T cells at different stages of differentiation toward acti-
vating and prompting CD4+ T cell differentiation in a
Th1-direction and producing Th1-type cytokines (IL-2,
IL-12, IFN-γ) [30-32]. Although the mechanism by
which CD8+ T cells mediate the inhibition of RSV
vaccine-enhanced pulmonary eosinophilia is currently
unknown, CD8+ cytotoxic C lymphocytes (CTLs) do ap-
pear to play an important role in regulating the immune
response through the secretion of cytokines, especially
IFN-γ [33]. Previous work by several laboratories has
shown that F- or M2-specific CD8+ T cell responses
inhibited RSV vaccine-enhanced pulmonary eosinophilia
because the production of IFN-γ can inhibit Th2-CD4+
T cell development in vitro [34]. Here, the number of
peripheral blood mononuclear cells (PBMCs) secreting
IFN-γ and IL-2 in response to RSV antigen indicated
that both rLong and its G-replacement mutant were
confirmed to produce CD8+ T cell immune responses
due to the secretion of IFN-γ and IL-2. Bukreyev re-
ported that RSV glycoprotein, through the cysteine-rich
region of G (“GCRR”), a segment conserved in wild-type
isolates worldwide, enhances the generation of an effect-
ive CTL response against RSV in BALB/c mice [33]. Our
rLong virus also stimulated a higher level of IFN-γ in
comparison with its G protein deletion form. We con-
sidered that one possible reason may be that the recom-
binant entire Long virus contains the GCRR, while the
sequence is absent in the ΔG mutant strain.
Another significant consideration for any RSV vaccine is
the balance of the immune response. Effective vaccines for
RSV must elicit balanced T cell responses. Immune re-
sponses dominated by type-2 T cells against RSV antigens
are believed to cause exaggerated respiratory tract disease
and may also contribute to inflammation [35]. Fin-
dings from several laboratories have established that
immunization with highly purified native or vaccinia
virus-expressed recombinant G protein primed naive
BALB/c mice for pulmonary eosinophilia upon subsequent
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reported that the immunization of BALB/C mice with
rA2cpΔG177-220 or rA2cpΔG150-222 was immunogenic,
and pulmonary eosinophilia was diminished significantly
[35]. Thus, the tendency of the rA2 strain with a G protein
mutation to elicit dominant type-2 responses was lessened
significantly with no apparent loss of immunogenicity. In
this study, serum IgG1 and IgG2a isotypes profiles indi-
cate a Th2- and Th1-type-biased response, respectively;
the levels were determined and the corresponding IgG1/
IgG2a ratio was calculated to evaluate the CD4+ T re-
sponse. Regarding the RSV Long strain, rLong and rLong-
ΔG-EGFP also resulted in predominantly Th1-type CD4+
T cell responses, shown the lower ratio of IgG1/IgG2a,
which was completely different from that with FI-RSV.
Also, levels of the IgG2a antibody related to a Th1-CD4+
T response in rLong-ΔG-EGFP-immunized mice was
higher than its counterparts. The region of amino acids
149–200 of the attachment (G) glycoprotein may be re-
sponsible for type-2 T cell responses and pulmonary eo-
sinophilia [39]. This indicates that a Th2 T cell response,
which is associated with pulmonary eosinophilia, could be
diminished with our ΔG Long strain.
In addition to possessing strong immunogenicity,
rLong-ΔG-EGFP performed better from the perspective
of a balanced Th1/Th2 response. However, other
research has shown that the RSV G glycoprotein is
not necessary for vaccine-enhanced disease induced
by immunization with FI-RSV [40,41]. RSV vaccine-
enhanced disease is not due to antigenic content, but ra-
ther concerns the pathway of antigen processing, and
thus G should not necessarily be excluded from poten-
tial vaccine products [40]. Polack also reported that the
GCRR of the G glycoprotein is a potent inhibitor of in-
flammatory cytokine production. By inhibiting Toll-like
receptor 4 (TLR4) activation and NF-κB nuclear trans-
location, it antagonizes the pro-inflammatory effect of
the F protein regulating the innate immune response, in-
dicating that it has broad anti-inflammatory properties;
therefore, the production of inflammatory cytokines re-
sponsible for pulmonary eosinophilia could be prevented
[42]. The role of G protein in inducing vaccine-
enhanced disease or whether G should be excluded from
RSV vaccine components needs to be clarified. Given
that the mechanism(s) of RSV vaccine-enhanced disease
is not understood, further exploratory efforts for RSV
vaccines are worthwhile. And also, For RSV vaccine can-
didate development, high levels of neutralizing anti-
bodies, CD8+ T cell responses, and a balanced T cell
response should be taken into consideration. This study
provides a platform for reverse genetics manipulation in
discovering “ideal” attenuated RSV candidates and also
allows examining the contribution of each viral compo-
nent to vaccine-enhanced disease.Conclusions
Using an optimized reverse genetics system for a negative-
strand RNA virus, rLong and rLong-ΔG-EGFP were con-
structed and recovered in Hep-2 cells. rLong-ΔG-EGFP
stably expresses EGFP even the G glycoprotein was de-
leted (ΔG). Animal experiments demonstrate that neither
recombinant virus is pathogenic and both have sufficient
immunogenicity, Also a Th1-CD4+ T-biased immune re-
sponse was induced by rLong-ΔG-EGFP. Moreover, no
detectable virus replication was found in the lungs, sug-
gesting that protection in the lower respiratory tract of
mice was excellent. This study also revealed that the inser-
tion of a foreign gene into the RSV genome was appar-
ently effective and safe, and we plan to evaluate this delta




The RSV Long strain (ATCC VR-26D) was provided by the
Wuhan Institute of Virology, Chinese Academy of Science
(Wuhan, China). Recombinant vaccinia virus vTF7-3 ex-
pressing bacteriophage T7 RNA polymerase was a gift from
Kunming Institute of Medical Biology, Chinese Academy of
Medical Sciences (Kunming, China). Hep-2 cells (ATCC
CCL-23) and Vero cells (ATCC CCL-81), provided by the
Wuhan Institute of Biological Products (Wuhan, China),
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% inactive fetal bovine serum (FBS;
Gibco-BRL, Gaithersburg, MD) at 37°C under an atmos-
phere of 5% CO2.
Construction of full-length cDNA clones of rLong and
rLong-ΔG-EGFP
The full-length antigenome of the RSV Long strain is
15,222-bp long (GenBank Accession No. AY911262.1).
The restriction site profile of this sequence was analyzed
using the primer 5.0 software. The restriction sites for
the cloning strategy are shown in the schematic diagram
(Figure 10A). A plasmid pBR322-linker, containing a T7
promoter sequence upstream of two essential functional
elements, HamRz and HdvRz, for the rescue of negative-
strand RNA virus in vitro was designed and constructed.
Based on this restriction map, an amplification scheme
was developed for the entire rLong and rLong-ΔG-EGFP
antigenome in which six distinct fragments were ampli-
fied using the primers in Table 3. Because fragment B
(C) contains an additional Nhe I (BamH I) restriction
enzyme cutting site; thus, six gene fragments need to be
compiled in the following order: F, E, D, C, B, and A,
when cloned into the pBR322-linker to obtain the full-
length cDNA clones (Figure 10B). First, PCR products of
the six gene fragments were cloned into the pMD19-T
simple vector for the construction of plasmids pT-A,
Figure 10 Cloning strategies for full-length cDNA of rLong and rLong-ΔG-EGFP. (A) Schematic diagram of rLong and rLong-ΔG-EGFP
full-length antigenomic cDNA, and the distribution of restriction enzyme sites within them. (B) The entire antigenome of long strain of RSV and
RSV replacement were amplified as six fragments (A-F), and these fragments were assembled in the pBR322-Linker vector according to a certain
order. the G gene was replaced with EGFP gene at fragment C (named as C1) to generate the complete cDNA clone of rLong-ΔG-EGFP.
(C) Schematic diagram showing the pBR322-Linker plasmid. The cassette comprising the T7 promoter, HamRz, seven site linker and HdvRz cDNA
sequences, and the full length cDNA of rLong or rLong-ΔG-EGFP was cloned into pBR322-Linker vector between restriction sites Sal I and Kpn I.
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fragments A, B, C, D, E, and F were obtained from the
corresponding T vector by restriction enzyme digestion
using Sal I/Bln I, Bln I/Xho I, Xho I/Not I, Not I/BamH
I, BamH I/Nhe I, and Nhe I/Kpn I, respectively. Finally,
each fragment was cloned sequentially into the corre-
sponding sites of the vector pBR322-linker to generateplasmid pBR322-FEDCBA (pRSV), which is the full-
length cDNA clone of the RSV Long strain (Figure 10C).
The G gene in the template vector pT-C with two re-
striction enzyme sites, Xho I and Not I, at the ends, was
replaced with the EGFP gene via an in-fusion cloning
technique: the cloning strategy is shown. The in-fusion
cloning technology has the advantage that is not limited
Table 3 Primers for amplification of RSV gene fragment
Primer name Primer sequence (5’-3’) Gene products (bp)
pF RSV-A ACGCGTCGACACGCGAAAAAATGCGTACAACAAAC 2130 bp
pR RSV-A AGCCCTAGGCCAGCAGCATTGCCTAATACTAC
pF RSV-B AGCCCTAGGCATAATGGGAGAGTACAGAGG 2323 bp
pR RSV-B CCGCTCGAGCTCTTGGTAACTCAAAGGTTTTG
pF RSV-C CCGCTCGAGTCAACACATAGCATTCATCAATC 1200 bp
pR RSV-C GCGGCCGCTTGTGATAATATGTTTTTTAATAAC
pF RSV-D GCGGCCGCGACCAACTCAAACAGAATCAAAAT 2800 bp
pR RSV-D CGCGGATCCATTTTGTCCCACAGCTTGAATTAT
pF RSV-E CGCGGATCCCATTATTAATGGAAATTCTGCTAA 2502 bp
pR RSV-E CTAGCTAGCAAATAATCTGCTTGAGCATGAGT
pF RSV-F CTAGCTAGCATTAAATAGCCTTAAATTACTGTA 4218 bp
pR RSV-F CGGGGTACCACGAGAAAAAAAGTGTCAAAAACT
All the primers were designed based on the whole sequence of long strain of Respiratory syncytial virus (GenBank Accession: AY911262.1). The restriction enzyme
sites within the primers are italic. “F” stands for forward and “R” stands for reverse to represent the direction of primer extension.
Figure 11 Schematic diagram for in-fusion cloning of pT-C1. The
strategy for in-fusion cloning to substitute EGFP of plasmid pT-C1 for G
gene in pT-C plasmid.
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5’-GTTTGCATTTGCCCCAACGTTATTGTTAGTCTT
G-3’ and pR1: 5’-TTATTAAAAAACATATTATCACAA
GCGGCCGCATC-3’, was designed for the amplification
of the vector fragment. Another pair of primers, pF2: 5’-
GGGGCAAATGCAAACATGGTGAGCAAGGGC-
GAGGAGCTG-3’ and pR2: 5’-TATGTTTTTTAATAAT-
TACTTGTACAGCTCGTCCATGCCG-3’, was designed
to generate the EGFP gene product. Both ends of the
vector fragment and the EGFP gene product were pro-
vided with an overlapped region comprising 15 bp.
Then, the plasmid pT-C1 containing the EGFP gene was
constructed using the In-Fusion™ cloning kit (Clontech,
Palo Alto, CA). Finally, plasmid pT-C1, containing the
EGFP gene, was digested with Xho I and Not I to
obtain plasmid pBR322 RSVΔG-EGFP (pRSVΔG-EGFP)
(Figure 11). The resulting pRSV and pRSVΔG-EGFP were
initially identified by Sal I/Kpn I digestion and then further
confirmed by DNA sequencing.
Construction of RSV helper plasmids
RSV N, P, and M2-1 genes were amplified by PCR with
following primer sets: for the N gene, N-F: 5’-CCGGAA
TTCATGGCTCTTAGCAAAGTCAAG-3’ and N-R: 5’-
CGGGGTACCTCAAAGCTCTACATCATTATC-3’; for
the P gene, P-F: 5’-CCTAGCTAGCATGGAAAAGTTT
GCTCCTGAA-3’ and P-R: 5’-CGGGGTACCTCAGAA
ATCTTCAAGTGATAG-3’; and for the M2-1 gene, M2-
1-F: 5’-CCGCTCGAGATGTCACGAAGGAATCCTTG
C-3’ and M2-1-R: 5’-CTAGTCTAGATCAGGTAGTAT
CATTATTTTTG-3’ (the underlined sequences indicate
restriction enzyme sites).
The N, P, and M2-1 gene products were cloned into
the pCI vector at the EcoR I/Kpn I, Nhe I/Kpn I, and
Xho I/Xba I sites, respectively. To construct L helperplasmids, two half-length fragments, L1 and L2, were
amplified by PCR and cloned into an intermediate T vec-
tor separately. Then L1 and L2 from plasmids pT-L1
and pT-L2 were assembled by stepwise subclonings into
the pCI vector at the Nhe I/Mlu I and Mlu I/Sal I sites,
respectively, to obtain the entire L gene. Consequently,
complete ORFs of the N, P, M2-1, and L gene were
inserted downstream of the CMV promoter of our
modified pCI vector to generate four helper plasmids
designated as pCI-N, pCI-P, pCI-M2-1, and pCI-L. Each
construct was confirmed by DNA sequencing.
Recovery of recombinant viruses
Recombinant RSVs were recovered from cDNA clones
largely as described before. The vTF7-3-infected Hep-2
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or pRSVΔG-EGFP) and a mixture of four helper plas-
mids expressing the N, P, L, and M2-1 proteins (desig-
nated as pCI-N, pCI-P, pCI-L, and pCI-M2-1; Figure 12).
These helper plasmids expressed structural protein
genes of the RSV Long strain. The transfection proced-
ure used was recommended by the supplier (Life Tech-
nologies, Carlsbad, CA). The amounts of plasmids added
were as follows: 1.6 μg pRSVΔG or pRSVΔG-EGFP,
1.6 μg pCI-N, 1.2 μg pCI-P, 0.4 μg pCI-L, and 0.8 μg
pCI-M2-1. After 4–6 h incubation, the medium was re-
placed with 3 ml DMEM (Life Technologies) containing
2% FBS and 40 mg of cytosine arabinoside per milliliter
medium to inhibit DNA polymerase activity. After 4 days
incubation at 37°C, the cultured supernatant containing
the rescued virus was harvested and then passaged to
fresh Hep-2 cells. Then, 3–5 days later, when cytopathol-
ogy was apparent, one-fifth of the medium supernatant
was passaged to another 25-cm2 flask of fresh cells for
viral multiplication.
The recovered recombinant viruses were further puri-
fied through multiple plaque purification procedures using
an overlay of Eagle’s minimal essential medium containing
2% FBS and 1.2% agarose. After 3–5 days incubation in 6-
well plates, the overlay was stained with 2 ml 0.05% neu-
tral red staining solution prepared in PBS for each well.Figure 12 Recovery of infectious recombinant RSV long virus entirely
encode a positive-sense copy of the viral genome (antigenome) of rLong o
nucleocapsid/polymerase complex. The expression of the cDNAs is under t
downstream end of the antigenome executes self-cleavage to produce a c
vTF7-3 vaccinia virus.Picking a single plaque from the 6-well plates into fresh
cells in 25-cm2 flasks, the culture supernatant was har-
vested when cytopathology was apparent. This procedure
was repeated 5–8 times to purify and amplify the rescued
virus. Moreover, cytosine arabinoside was also maintained
for each passage of the recovered virus.
Characterization of recombinant viruses
To examine the successfully recovered recombinant virus,
3-day post-transfected Hep-2 cells, which were infected
with rLong for viral propagation, were fixed with 80%
acetone at 4°C for 30 min, then stained with an anti-RSV
G1 polyclonal antibody (a polyclonal antibody against
RSV G protein epitopes prepared in rabbit in our labora-
tory), and finally incubated with sheep anti-rabbit im-
munoglobulin G labeled with HRP at a dilution of 1:5000.
Additionally, the recovered rLong-ΔG-EGFP was exam-
ined directly for the expression of EGFP in infected Hep-2
cells under a fluorescence microscope.
To identify specific genes of recovered rLong or rLong-
ΔG-EGFP, total RNA was extracted from the supernatant
of the infected Hep-2 cells. Reverse transcription (RT)-
PCR was performed with one pair of primers: positive-
sense, RSV-G-F (5’-ATGTCCAAAAACAAGGACCAAC
G-3’) and negative-sense, RSV-G-R (5’-CCCAACACAA
CACGCCAGTAG-3’) to amplify the G gene. Another pairfrom cloned cDNAs. The five cDNAs are indicated by rectangles and
r rLong-ΔG-EGFP and mRNAs for the N, P, L, and M2-1 proteins of the
he control of T7 promoter, The indicated ribozyme encoded at the
orrect 3’end. The T7 RNA polymerase can be provided intracellularly by
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GGCGAGGAG-3’) and negative-sense: EGFP-R (5’-CTTG
TACAGCTCGTCCATGCC-3’), was designed to amplify
the EGFP gene. PCR was carried out for 30 cycles with the
profile for both G and EGFP genes: denaturation at 94°C
for 40s, annealing at 55°C for 30 s, and elongation at 72°C
for 1 min. PCR products were analyzed by electrophoresis
on 1% agarose gels before sequencing. To eliminate any in-
fluence of false-positives that may be caused by template
pRSV and pRSVΔG-EGFP, total RNA extracted from the
supernatant of Hep-2 cells, infected with rLong or rLong-
ΔG-EGFP, was treated with RNase-free DNase I at 37°C for
30 min and then purified through phenol–chloroform ex-
traction and isopropanol precipitation procedures to get
clean RNA without template DNA contamination.
Viral titration
The viral titer was determined by a plaque assay and
expressed as PFU. The virus was tenfold serially diluted
with 2% FBS in DMEM and then added to Hep-2 mono-
layer cells. After a 1-h incubation at 37°C, the culture was
removed and replaced with 3 ml of overlay containing 1%
methylcellulose prepared in DMEM supplemented with
2% FBS. Hep-2 cells continued to be cultured at 37°C in
an atmosphere of 5% CO2, and the cytopathic effect was
observed under a microscope. After 4–7 days incubation,
Hep-2 cells were fixed with 20% formaldehyde for 30 min
and stained with 0.1% crystal violet to calculate the num-
ber of plaques with appropriate dilutions. The number of
plaques is preferably 10–50 per well for an optimal virus
dilution. To determine RSV titers in lungs, BALB/c mice
were killed and the lungs were removed, weighed, homog-
enized in stabilizing buffer, and stored at −80°C. RSV titers
in lungs were determined on Hep-2 cells and expressed in
log10 PFU per gram lung. The lower detection limit in
lungs was 2.68 log10 PFU g
−1. To determine RSV titers in
the nose, nasal tissue lavage (NTL) were obtained by
flushing the upper trachea with 1 ml PBS solution. The
lower detection limit in the nose was 1.86 log10 PFU ml
−1.
Immunizations and virus challenge
BALB/c mice (6–8 weeks old) were obtained from the Ex-
perimental Animal Center of Wuhan University and were
specific-pathogen-free. Mice were i.n. on days 0, 7, and 14
with 105 PFU rLong, rLong-ΔG-EGFP, or FI-RSV prepara-
tions. The wild-type RSV Long virus was inactivated with
0.1% formaldehyde at 37°C for 48 h, and the final inocula-
tion amount for each animal with FI-RSV was the same as
the viral titers before inactivation. Each experimental
group consisted of a total of 30 animals. At 10 days after
all immunization procedures were completed, 20 animals
per group for the protectivity study were challenged intra-
nasally with 106 PFU RSV Long strain preparations.
“Mock” control animals were inoculated with culturesupernatants of Hep-2 cells and challenged with the same
RSV preparations.
Serum neutralizing antibodies against RSV
BALB/c mice (6–8 weeks old) were housed in groups of
four under pathogen-free conditions; each group con-
sisted of 10 mice. Experimental groups were immunized
with 105 PFU viral antigens (FI-RSV, rLong, rLong-ΔG-
EGFP) per mouse by intranasal injection three times
with a 7-day interval. Mock controls were inoculated
with culture supernatants of Hep-2 cells. Ten days after
all immunization procedures had been completed, mice
were killed and blood serum was separated, lung tissue
was homogenized with a homogenizer, and the super-
natant was collected by centrifugation. nasal tissue lav-
age (NTL) was prepared by flushing the nasal cavity
with 1 ml PBS solution. Levels of neutralizing antibodies
in immunized mice serum, lung, and NTL were deter-
mined by plaque reduction assays.
Threefold serial dilutions, starting at 1:1, of mice
serum were prepared in virus diluents (DMEM supple-
mented with 2% FBS). Each serum dilution was mixed
with an equal volume of virus and incubated for 1 h at
37°C. Hep-2 monolayers, prepared in 96-well plates were
infected with 50 μl/well (in triplicate) of the serum/virus
mixture. The final amount of virus in each well of the
96-well plate was 100 plaques. After incubation for 1 h
at 37°C, the supernatant was removed, and cells were
overlaid with 1.0% methylcellulose prepared in DMEM
supplemented with 2% FBS. Then, 3 days later when the
cytopathic effect was apparent, the overlay was removed
and cells were fixed with 20% formaldehyde–PBS and
stained with 1% crystal violet in PBS containing 20%
ethanol. Plaques were counted, and titers of neutralizing
antibodies were analyzed by a regression analysis to de-
termine the 60% plaque reduction titer (log3).
Protectivity of recombinant viruses
The immunization strategy for the immune protectivity
study was similar to that of the immunogenicity studies.
Each group for the protectivity study consisted of 20 ani-
mals. At 10 days after all immunization procedures were
completed, mice were challenged with 106 PFU Long
virus and killed on days 3, 5, 7, and 10 post-challenge to
measure the changes in neutralizing antibody titers in
serum, and at the same time, the residual virus titers in
lung tissue and NTL were also determined at the indi-
cated times post-challenge.
IgG1 and IgG2a antibody responses to the virus in mice
sera samples
Antiviral serum antibody subtype IgG1 and IgG2a titers
in mice pre-immunized with FI-RSV, rLong, and rLong-
ΔG-EGFP were measured in terms of IgG1 and IgG2a
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cording to the manufacturer’s protocol. At the same
time, the IgG1 and IgG2a antibody titers at the indicated
times post-challenge were determined, and the ratio of
IgG1/IgG2a was calculated to evaluate the Th1/Th2 im-
mune response.ELISPOT assay of spleen cells in mice immunized with
recombinant viruses
Specific cellular immune responses with the secretion of
IFN-γ and IL-2 were determined by ELISPOT assays.
Mouse IFN-γ-precoated ELISPOT kit (Dakewe, Shenzhen,
China) and an IL-2-precoated ELISPOT kit (Abcam, UK)
were used according to the manufacturers’ instructions.
Briefly, 96-well flat-bottomed microtiter plates were prein-
cubated with the coating antibody (anti-IFN-γ or anti-IL-2
monoclonal antibody) at 4°C overnight and blocked for 2 h
at 37°C. Splenocytes from mice that were vaccinated
with FI-RSV, rLong, or rLong-ΔG-EGFP at a density of
2–5 × 105 cells per well were added to wells in triplicate,
stimulating with RSV antigen preparations separately,
and incubated at 37°C, 5% CO2 for 24 h. Phorbol myris-
tate acetate (PMA) and concanavalin A (ConA; Sigma,
St. Louis, MO) were used as positive controls. Then,
cells were removed, wells were washed 10 times with
PBS containing 0.05% Tween 20 (PBST), and incubated
with 100 μl biotinylated anti-IFN-γ or anti-IL-2 anti-
body for 1 h. The plates were washed again with PBST
and incubated with 50 μl HRP–streptavidin solution at
37°C for 1 h. SFCs were counted and analyzed with an
ELISPOT plate reader. Results are presented as SFCs
per 106 cells (SFCs/106 cells).
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